Good health is of paramount importance to our everyday lives. Correct diagnosis of illnesses and diseases needs to be made, appropriate drugs, technologies and treatments need to be readily available to treat and cure any afflictions which befall us.
EU funding in 2010
€ 772.39 million
The EU devotes 11% of the total FP7 budget to optimise healthcare delivery in Europe by developing diagnostic and monitoring tools, therapeutic techniques, drugs and methodologies. Its research results can inspire and influence health policy and thus provide added value to Member States' actions and efforts. This EU's investment in health research also intends to boost the competitiveness and the innovative capacity of European health-related industries and businesses.
The Innovative Medicines Joint Undertaking (IMI JU), a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), sets out to improve the efficiency and effectiveness of drug development. It currently supports 15 research projects. More effective and safer innovative medicines will enable patients to obtain the most appropriate treatment and therapy available. Resources are provided from industry, academia, SMEs, regulatory authorities, healthcare providers and patients' organisations. In 2010, the first interim evaluation of the IMI JU by independent experts concluded that it had a high potential for achieving its goals.